Definition/General

Introduction:
-Radiation-induced changes in urine cytology represent iatrogenic cellular alterations following radiotherapy
-These changes result from DNA damage and cellular injury
-Acute and chronic phases show different morphological features
-Recognition prevents misinterpretation as malignancy.
Origin:
-Changes originate from ionizing radiation damage to urothelial cells
-DNA strand breaks and chromosomal abnormalities occur
-Cellular repair mechanisms become overwhelmed
-Vascular damage contributes to tissue injury
-Chronic inflammation and fibrosis develop.
Classification:
-Classified by temporal relationship to radiation
-Acute changes (within days to weeks)
-Subacute changes (weeks to months)
-Chronic changes (months to years)
-Early delayed effects
-Late delayed effects.
Epidemiology:
-Occurs in 20-40% of patients receiving pelvic radiation
-More common with higher radiation doses (>50 Gy)
-Concurrent chemotherapy increases risk
-Previous pelvic surgery increases susceptibility
-Age and comorbidities influence severity
-Diabetes increases risk.

Clinical Features

Presentation:
-Acute cystitis symptoms (dysuria, frequency)
-Hematuria (microscopic or gross)
-Urgency and nocturia
-Suprapubic pain
-Reduced bladder capacity
-Chronic pain syndrome possible
-Secondary infections common.
Symptoms:
-Urinary frequency and urgency
-Dysuria (painful urination)
-Hematuria (blood in urine)
-Pelvic pain
-Nocturia (nighttime urination)
-Urinary incontinence
-Tenesmus (incomplete emptying sensation).
Risk Factors:
-High radiation dose (>50 Gy)
-Large treatment volume
-Concurrent chemotherapy
-Previous pelvic surgery
-Diabetes mellitus
-Advanced age
-Smoking
-Poor nutritional status
-Genetic susceptibility.
Screening:
-Regular urinalysis during treatment
-Cytological monitoring
-Symptom assessment scales
-Cystoscopy for severe cases
-Imaging studies when indicated
-Functional assessments.

Master Radiation Cystitis Changes Pathology with RxDx

Access 100+ pathology videos and expert guidance with the RxDx app

Gross Description

Appearance:
-Hematuria ranging from pink to dark red
-Cloudy urine with increased cellularity
-Proteinuria may be present
-Debris and inflammatory material
-Normal color possible in mild cases
-Foamy appearance due to protein.
Characteristics:
-Increased specific gravity
-Protein and blood positive
-Cellular debris abundant
-Inflammatory exudate
-Variable pH levels
-Bacterial contamination possible.

Microscopic Description

Immunohistochemistry

Positive Markers:
-p53 (accumulation due to DNA damage)
-γH2AX (DNA damage marker)
-Ki-67 (variable proliferation)
-CK7 and CK20 (urothelial origin)
-Uroplakin
-PCNA (proliferation marker).
Negative Markers:
-p16 (usually negative)
-High-risk HPV markers
-CEA (typically negative)
-TTF-1 (negative)
-PSA (negative)
-Chromogranin (negative).
Diagnostic Utility:
-p53 accumulation indicates DNA damage
-γH2AX confirms radiation exposure
-Ki-67 shows variable patterns
-Helps distinguish from malignancy
-CK7/CK20 confirm urothelial origin
-Clinical correlation essential.

Molecular/Genetic

Differential Diagnosis

Similar Entities:
-High-grade urothelial carcinoma
-Viral cytopathic effects
-Chemotherapy-induced changes
-Reactive atypia
-Inflammatory changes
-Instrumentation trauma.
Distinguishing Features:
-Radiation changes: History of radiation, bizarre giant cells
-Carcinoma: Monotonous population, irregular chromatin
-Viral: Specific inclusions, immunostains positive
-Chemotherapy: Drug history, different morphology
-Reactive: Inflammatory background.
Diagnostic Challenges:
-Severe atypia may mimic malignancy
-Bizarre cells very concerning morphologically
-Mixed changes complicate interpretation
-Temporal relationship to radiation important
-Secondary malignancy possible.

Sample Pathology Report

Template Format

Sample Pathology Report

Complete Report: This is an example of how the final pathology report should be structured for this condition.

Specimen Information

Urine specimen, [collection method], [volume] ml

Clinical History

History of pelvic radiation therapy [dose and timeline]

Specimen Adequacy

Adequate for cytological evaluation

Radiation Changes

Urothelial cells showing radiation-induced changes with [specific features]

Cellular Features

[describe specific morphological changes]

Background

[degree] inflammatory background with [components]

Diagnosis

Radiation-induced changes, [acute/chronic phase]

Differential Diagnosis

No evidence of malignancy. Consider [relevant differentials]

Recommendations

Clinical correlation. Follow-up cytology. Consider cystoscopy if indicated.